PPARγ agonists have been proposed to be promising candidate drugs in the treatment of HIV-1 brain inflammation and neurocognitive outcomes [86], especially as they are already being used in treatment of HIV-associated lipodystrophy [121]. Here, PPARG is linked to lipodystrophy.